Ranking

Best Semaglutide Telehealth Providers 2026, Ranked on What You Can Check

We rank on six tests, each of which exists because a published figure failed it: captured at source, publishes a maintenance-dose price, one published structure, names it

Why is this not ranked on price alone?

A price is one field. It is also the field most likely to be wrong: we have watched one provider's reported price move 66% in five days, another publish six simultaneous structures selected by landing page, and a headline turn out to be a different molecule entirely.

So the ranking runs on what a reader can independently check.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

The pricing, for the providers that publish it

Plan totals as published: $447 for three months, $882 for six, $1,740 for twelve. Each reconciles exactly against its monthly rate. The sublingual 3-month plan does not — it states a $597 total against a $185 monthly rate, which multiplies to $555. We record the monthly rate and have asked for the total to be corrected. COR-012.

What does each test actually check?

1. Captured at source. We opened the provider's own page, read the figure and archived it with a date. A number from a roundup is a different object.
2. Publishes a maintenance-dose price. Semaglutide titrates over 16 to 20 weeks. A provider publishing only an entry price has not told you what treatment costs.
3. One published structure. Not a different price depending on which campaign page you arrive through.
4. Names its fulfilling pharmacy. A named pharmacy can be checked against its state board and the FDA warning-letter database. An unnamed one cannot be checked at all.
5. Answered all four disclosure questions. Pharmacy, clinical model, state licensure, refund terms.
6. No figure we had to withdraw. No price attributed to this provider failed a check and came off the site.

What is the salt-form question?

Its sodium and acetate salts are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. A salt form is a different chemical entity; it has not been through the safety or efficacy review the base went through.

Ask for the exact salt form and concentration in writing before you buy. A provider that cannot answer in writing has told you something. There is no tirzepatide equivalent of this question, which is why it belongs on every semaglutide page and on none of the tirzepatide ones.

What can no ranking tell you?

Whether a specific vial contains what its label says. Whether a prescriber genuinely read your intake. Whether a pharmacy's sterility practice met USP <797> on the day your batch was made. No comparison site can establish those, and one implying otherwise is overstating what a desk review does.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Frequently asked questions

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.